[Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].

Immune checkpoint inhibitors (ICIs)-based immunotherapy combined with other treatment for hepatocellular carcinoma (HCC) has achieved significant efficacy in clinical research and practice, and has become the most commonly used and mainstay therapy for the treatment of unresectable HCC. In order to help clinicians administrating immunotherapy drugs and regimens rationally, effectively and safely, we organized a multidisciplinary expert team to adopt the "Delphi" consensus formation method, and finally revised and completed the "Multidisciplinary Expert Consensus on Combination Therapy Based on the Immunotherapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 version. This consensus mainly focuses on the principles and methods of clinical application of combination therapy based on the Immunotherapy, aiming to summarize the recommendations for clinical application based on the latest research and expert experience, and provide application guidance for clinicians.基于免疫节点抑制剂（ICIs）的肝细胞癌免疫联合治疗在临床研究和临床实践中已取得了显著的疗效，且已成为目前不可切除肝细胞癌治疗的最常用和最主要的疗法。为了更好地帮助临床医师合理、有效、安全地应用免疫联合治疗药物和方案，编委会组织了本领域的多学科专家团队共同进行研讨，采用"德尔菲(Delphi)"共识形成方法，在2021版基础上最终修订完成了《肝细胞癌免疫联合治疗多学科中国专家共识（2023版）》。该共识主要聚焦于ICIs联合疗法临床应用的原则和方法，旨在结合最新的研究进展和专家经验总结归纳出临床应用的推荐意见，为肝癌治疗专业人员提供临床应用依据。.